Palivizumab shows promise for preventing repeated wheezing in preemies

10/14/2013 | DailyRx.com

Babies born between 33 weeks and 35 weeks of gestation who were given palivizumab within their first six months of life were less likely to develop recurrent wheezing during their first three years than those who did not get the medication, a Japanese study in the journal Pediatrics showed. Of the 349 babies in the palivizumab group, 6.4% had repeated wheezing compared to nearly 19% in the control group.

View Full Article in:

DailyRx.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD